Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Q2 Half Year Report 2021

August 5, 2021

Q1 Report 2021

May 6, 2021

Investor presentations

Corporate Deck March 2021

HCW Presentation March 9, 2021

SVB Leerink Presentation Feb 24, 2021

Corporate Deck February 2021

Corporate Deck January 2021

JPM Presentation Jan 14, 2021

Investor Deck December 2020

Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids

1 2 3 4 5

Press Releases

ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix

press release

October 13, 2021

-Linzagolix, an oral GnRH antagonist, is pending regulatory approval in the U.S. and Europe for the treatment of uterine fibroids-…

Read more

ObsEva Announces Appointment of Luigi Marro as Chief Transformation Officer

press release

September 30, 2021

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   GENEVA, Switzerland – September 30, 2021…

Read more

ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids

press release

September 15, 2021

-If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of…

Read more
1 2 3 65

General Meetings

ObsEva Extraordinary General Meeting 2018

January 28, 2018

Read more

ObsEva Annual General Meeting 2017

June 13, 2017

Read more
1 2 3

Upcoming Events

Sorry, there are no events available yes.

 

Contacts

ObsEva Switzerland Office

Chemin des Aulx,12

1228, Plan-Les-Ouates, Geneva, Switzerland

+41 (0)22 552 3840


contact@obseva.ch

Media

Shauna Dillon

+41 (0)22 552 1550 Office

+41 79 360 3533 Mobile

shauna.dillon@obseva.ch

Investor relations


.


Joyce Allaire

+1 (617)-435-6602

ir@obseva.ch

Clinical studies




clinicaltrials@obseva.ch

HR Office

Charlotte Cadoux


charlotte.cadoux@obseva.ch

CEO Office

+41 (0)22 552 1550


shauna.dillon@obseva.ch

 

Sign up for news

 
 

    * Type:


    InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












    Read our privacy policy here.


     

    Are you sure you want to leave ObsEva.com?

    We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

    Continue to link

    Disclaimer

    Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

    Continue

    Disclaimer

    Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

    Continue